Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kura Oncology (KURA) Cash & Equivalents (2022 - 2026)

Kura Oncology has reported Cash & Equivalents over the past 5 years, most recently at $39.1 million for Q1 2026.

  • Quarterly Cash & Equivalents fell 23.77% to $39.1 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $39.1 million through Mar 2026, down 23.77% year-over-year, with the annual reading at $149.1 million for FY2025, 33.57% down from the prior year.
  • Cash & Equivalents was $39.1 million for Q1 2026 at Kura Oncology, down from $149.1 million in the prior quarter.
  • Over five years, Cash & Equivalents peaked at $224.5 million in Q4 2024 and troughed at $27.1 million in Q1 2023.
  • The 5-year median for Cash & Equivalents is $49.3 million (2023), against an average of $69.4 million.
  • Year-over-year, Cash & Equivalents skyrocketed 501.48% in 2024 and then plummeted 33.57% in 2025.
  • A 5-year view of Cash & Equivalents shows it stood at $51.8 million in 2022, then fell by 27.96% to $37.3 million in 2023, then skyrocketed by 501.48% to $224.5 million in 2024, then plummeted by 33.57% to $149.1 million in 2025, then crashed by 73.79% to $39.1 million in 2026.
  • Per Business Quant, the three most recent readings for KURA's Cash & Equivalents are $39.1 million (Q1 2026), $149.1 million (Q4 2025), and $95.3 million (Q3 2025).